XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)

Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details) $ / shares in Units, $ in Thousands			3 Months Ended					6 Months Ended		12 Months Ended
	Apr. 03, 2024 USD ($) Right $ / shares shares	Feb. 27, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Nov. 10, 2023 USD ($)
Asset acquisition
Exarafenib milestone asset			$ 2,922	$ 2,922				$ 2,922
Exarafenib milestone contingent consideration			2,922	2,922				2,922
Operating lease liabilities			1,131	1,131				1,131		$ 400	$ 400
Purchase consideration
Operating lease right-of-use assets			349	349				349		378	$ 400
Allocation of purchase consideration
Cash and cash equivalents			143,904	143,904				143,904		153,290
Prepaid expenses and other current assets			2,820	2,820				2,820		483
Exarafenib milestone asset			2,922	2,922				2,922
Accrued and other liabilities			(4,869)	(4,869)				(4,869)		(2,768)
Operating lease liabilities			(421)	(421)				(421)		(54)
Long-term operating lease liabilities			(710)	(710)				(710)		(335)
Less: Gain on the acquisition of Kinnate			(19,316)					(19,316)
Net Income (Loss)			15,985		$ (8,595)	$ (5,400)	$ (9,813)	7,390	$ (15,213)
Revenues			11,086			$ 1,658		12,576	$ 2,095
Exarafenib and related IP \| CVR Agreement \| Kinnate
Asset acquisition
Percentage of further net proceeds from sale		100.00%
Percentage of net proceeds from any license or other disposition		85.00%
Exarafenib and related IP \| Disposed of by Sale, Not Discontinued Operations \| Kinnate
Asset acquisition
Cash consideration received		$ 500
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company		30,500
Kinnate
Asset acquisition
Asset acquisition, Share price (in dollars per share) \| $ / shares	$ 2.5879
Number of non-transferable contractual CVR per share of Kinnate common stock \| Right	1
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company	$ 30,500
Exarafenib milestone asset	2,922		2,900	2,900				2,900
Exarafenib milestone contingent consideration			2,900	2,900				2,900
Operating lease liabilities	800
Purchase consideration
Closing cash payment	122,646
Estimated fair value of the Exarafenib milestone contingent consideration	2,922
Transaction costs	809
Total purchase consideration	$ 126,377
Kinnate common stock tendered \| shares	47,232,737
Total number of underlying shares \| shares	2,510,552
Fair value of the IPR&D asset	$ 0
Intangible assets	0
Operating lease right-of-use assets	0
Allocation of purchase consideration
Cash and cash equivalents	142,381
Prepaid expenses and other current assets	3,223
Exarafenib milestone asset	2,922		$ 2,900	2,900				2,900
Accrued and other liabilities	(2,009)
Operating lease liabilities	(322)
Long-term operating lease liabilities	(502)
Net assets acquired	145,693
Less: Gain on the acquisition of Kinnate	(19,316)
Total purchase consideration	126,377
Severance charges				$ 3,600
Severance charges paid								3,600
Kinnate \| Pro forma
Allocation of purchase consideration
Net Income (Loss)								7,400		25,100
Kinnate \| Adjustment
Allocation of purchase consideration
Revenues								$ 0		$ 0
Kinnate \| CVR Agreement
Asset acquisition
Contingent consideration from the Exarafenib Sale payable from the Company to the Kinnate CVR Holders under the CVR Agreement	$ 30,500
Kinnate \| Exarafenib and related IP \| Disposed of by Sale, Not Discontinued Operations
Asset acquisition
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company		$ 30,500